Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - atazanavir sulfate; cobicistat - tablet - 300mg ; 150mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - tenofovir alafenamide; emtricitabine; cobicistat; elvitegravir - tablet - 10mg ; 200mg ; 150mg ; 150mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - idelalisib - tablet - 100mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - idelalisib - tablet - 150mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - cobicistat; emtricitabine; tenofovir alafenamide fumarate; darunavir ethanolate - tablet - 150mg ; 200mg ; 10mg ; 800mg

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - darunavir - film-coated tablet - 600 milligram(s) - protease inhibitors; darunavir

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - darunavir - film-coated tablet - 800 milligram(s) - protease inhibitors; darunavir

Malaysia - Inggris - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn. bhd. - darunavir -

Malta - Inggris - Malta Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - darunavir propylene, glycolate - film-coated tablet - darunavir propylene glycolate 600 mg - antivirals for systemic use

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - tenofovir alafenamide, quantity: 10 mg; darunavir, quantity: 800 mg; cobicistat, quantity: 150 mg; emtricitabine, quantity: 200 mg - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; silicon dioxide; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - symtuza is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg). genotypic testing should guide the use of symtuza (see section 4.2 dose and method of administration, section 4.4 special warnings and precautions for use and section 5.1 pharmacodynamic properties).